Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Selecting Patients with Advanced NSCLC for Chemo

JAMA Oncol; ePub 2017 Nov 1; Shen, Chang, et al

Certain small metabolites could serve as useful biomarkers to help select ideal candidates for platinum-based chemotherapy in patients with non-small cell lung cancer (NSCLC), according to a study involving 220 individuals. Participants had advanced-stage NSCLC with either poor (n=110) or good survival (n=110). Investigators performed metabolomic profiling and then looked at the link between certain metabolites and survival during discovery and validation phases. Among the results:

  • The levels of caffeine, paraxanthine, stachydrine, and methyl glucopyranoside (alpha + beta) metabolites were substantially different between patients with poor and good survival during both discovery and validation.
  • Increased levels of the 4 metabolites were significantly linked with good survival in both discovery and validation phases.
  • Strong cumulative effects on overall survival were also seen.
Citation:

Shen J, Chang D, Huang M, et al. Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapy. [Published online ahead of print November 1, 2017]. JAMA Oncol. doi:10.1016/j.lungcan.2017.10.018.

This Week's Must Reads

Cochrane on Bisphosphonates for Breast Cancer, Cochrane; 2017 Oct 30; O'Carrigan, Wong, et al

Fiber Intake and Survival After CRC Diagnosis, JAMA Oncol; ePub 2017 Nov 2; Song, Wu, et al

Selecting Patients with Advanced NSCLC for Chemo, JAMA Oncol; ePub 2017 Nov 1; Shen, Chang, et al

Predicting CV Risk in Childhood Cancer Survivors, J Clin Oncol; ePub 2017 Nov 2; Chow, Chen, et al

CD8+ Tumor-Infiltrating Lymphocytes and Ovarian Ca, JAMA Oncol; ePub 2017 Oct 12; OTTA Consortium

Must Reads in Lung Cancer

Selecting Patients with Advanced NSCLC for Chemo, JAMA Oncol; ePub 2017 Nov 1; Shen, Chang, et al

Durvalumab Post-Chemoradiotherapy in NSCLC Assessed, N Engl J Med; ePub 2017 Sep 8; Antonia, et al

Cochrane on Heparin Impact in People with Cancer , Cochrane; 2017 Sep 11; Akl, Kahale, et al

FDA Approves First Biosimilar to Treat Cancer, FDA news release; 2017 Sep 14

ASCO Updates Stage IV NSCLC Treatment Guideline, J Clin Oncol; ePub 2017 Aug 14; Hanna, et al